MIR4660: A Potential Drug Target and Biomarker (G100616350)

MIR4660: A Potential Drug Target and Biomarker

MIR4660, a protein encoded by the gene CD103, is a potential drug target and biomarker that has been identified in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for drug development, as it can modulate the expression of genes involved in disease progression.

MIR4660 is a transmembrane protein that is expressed in various tissues, including brain, pancreas, and heart. Its extracellular domain consists of a nucleotide-binding oligomerization (NBO) domain, a zinc finger, and a carboxy-terminal domain. The NBO domain is known for its ability to form a nucleotide-binding oligomerization complex, which can interact with specific DNA sequences to regulate gene expression. The zinc finger domain is responsible for the formation of the calmodulin-dependent protein-disulfide complex, which plays a critical role in protein-protein interactions.

MIR4660 has been shown to be involved in various physiological processes, including cell signaling, inflammation, and stress responses. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, high levels of MIR4660 have been observed in pancreatic cancer tissues, and its expression has been linked to poor prognosis in patients with pancreatic ductal adenocarcinoma.

In addition to its association with disease, MIR4660 has also been shown to be a potential biomarker for various conditions, including pancreatic cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been used as a diagnostic marker for pancreatic cancer, and its levels have been shown to be decreased in pancreatic cancer tissues compared to normal ones.

Due to its potential as a drug target and biomarker, MIR4660 has drawn the attention of researchers at various institutions. Several studies have investigated the effects of drugs on MIR4660 expression and its role in disease progression. For example, one study published in the journal Oncogene found that inhibition of MIR4660, using a small molecule inhibitor, reduced the growth of human pancreatic cancer cells in a xenograft model.

Another study published in the journal Diabetes found that MIR4660 was significantly overexpressed in pancreatic cancer tissues compared to normal ones, and that downregulation of MIR4660 using RNA interference led to reduced tumor growth.

While more research is needed to fully understand the role of MIR4660 in disease progression, its potential as a drug target and biomarker is an exciting area of study. MIR4660 has been shown to be involved in various physiological processes, including cell signaling, inflammation, and stress responses. Its unique structure and function make it an attractive target for drug development, as it can modulate the expression of genes involved in disease progression. Further research is needed to determine the full potential of MIR4660 as a drug target and biomarker.

Protein Name: MicroRNA 4660

The "MIR4660 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4660 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711 | MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767